Acute myeloid leukemia (AML) is a heterogeneous disease. Among chromosomal numerical aberrations, trisomy 8 ( þ 8) is the most common chromosomal change, conferring an intermediate prognosis, and is associated with the t(7;12), t(9;11) and t(1;11) translocations. 1 Alone, trisomy 8 does not appear to be sufficient for leukemogenesis but may be associated with an increased risk of myeloid malignancy. 1 To investigate further the contribution of þ 8 to AML, we determined the gene expression signature associated specifically with this numerical chromosomal abnormality using large, previously reported, AML microarray data sets 2, 3 and data sets derived from AML cell lines. We have identified a novel association between HOXA gene upregulation and þ 8 AML providing new insight into the potential contribution of þ 8 to AML pathogenesis.
We first analyzed the large AML microarray data set (Affymetrix HGU133A, Santa Clara, CA, USA) from the study by Valk et al.
2 (GSE1159). Criteria for inclusion were patients with a þ 8 karyotype without any other karyotypic abnormalities, such as translocations, or other numerical chromosomal aberrations. Patients with a þ 8 karyotype and mutations in FLT3, EVI1, RAS, CEBPA or NPM1 genes were not excluded. Data were normalized with Robust Multichip Average (RMA) and the gene expression change for each gene determined in the þ 8 AML group (n ¼ 16), relative to the expression level in normal bone marrow mononuclear cells (NBM, n ¼ 5). This approach focused on genes in the selected AML group that may contribute to the leukemic phenotype by virtue of their association with the block in differentiation, increased selfrenewal, increased survival and proliferative potential. To generate the final þ 8 AML gene set, we selected genes that are selectively differentially expressed in þ 8 AML compared to NBM but not differentially expressed in the other common AML numerical chromosome abnormalities, monosomy 7 (À7) and À7q. Analysis was performed using linear modeling analysis package available from the Bioconductor (http://www. bioconductor.org/). Genes with multiple probes were filtered based on an adjusted false discovery rate P-value controlled using Benjamini-Hochberg method. The analysis was performed using R (http://www.r-project.org/). This approach identified 90 genes (false discovery rate P-value o0.01) that display selective differential gene expression in AML associated with trisomy 8 (Figure 1 ). The top 10 up-and downregulated genes ranked based on fold change are shown in Table 1 .
Seven of the differentially regulated genes were located on chromosome 8 (marked with a double asterisk in Figure 1 ) and, as may be predicted from the þ 8 genotype and shown by previous gene expression studies (reviewed by Paulsson and Johansson 1 ), the expression of six of these was upregulated. Unsupervised clustering with MeV (http://www.tm4.org/mev/) using the þ 8 AML gene signature showed that þ 8 AML clustered together with the mixed-lineage leukemia (MLL) translocation group and with normal karyotype AML (Figure 1 ) This is in line with the clinical findings that þ 8, MLL and normal karyotype AML form a well-defined prognostic group (G1) with intermediate outcome 4 ( Figure 1 ). Of significant interest, we identified several HOX genes (HOXA9, HOXA10 and HOXA1) that display increased expression in the þ 8 AML group relative to most other karyotypic groups and NBM ( Figure 2 ). Several HOX genes from the HOXA cluster, in particular HOXA9, have important roles in hematopoiesis and leukemogenesis. 5 This is the first report of increased HOX gene expression as a feature of þ 8 AML, although increased HOX gene expression has been reported in AML with MLL rearrange-ments and normal karyotype. 5 The most likely explanation for the previously unrecognized association between HOXA gene expression and þ 8 AML is that previous þ 8 AML gene expression profiling studies 1 have compared þ 8 gene expression to AML with normal karyotype, a group that also displays relatively high levels of HOXA gene expression ( Figure 2 ).
We next examined expression in a leukemia cell line expression data set (https://cabig.nci.nih.gov/caArray_GSKdata/) and another large AML microarray data set (GSE6891). 3 Both microarray data sets were normalized using the RMA algorithm.
Cell lines were grouped based on presence or absence of þ 8 and the normalized expression of HOXA9 and HOXA10 plotted for each line (Figure 3a ). When expression data was grouped into those cell lines with þ 8 karyotype and compared to those without þ 8 karyotype, we found a highly significant increase in HOXA9 (P ¼ 0.0003) and HOXA10 (P ¼ 0.0002) expression in cell lines with þ 8 (data not shown). Because high HOXA expression is known to be associated with the MLL translocation (see Figure 2) , we also compared cell lines with and without MLL lesions ( Figure 3b ). As expected, MLL cell lines, irrespective of their þ 8 status, have high HOXA9 and HOXA10 expression, suggesting that higher expression of HOXA9 and HOXA10 in MLL is independent of the þ 8 lesion. However, in the absence of an MLL lesion, þ 8 cell lines still expressed significantly higher HOXA9 (P ¼ 0.0009) and HOXA10 (P ¼ 0.0024) levels compared to cell lines without the þ 8 lesion (Figure 2b ). Thus HOXA gene expression is independently associated with þ 8 and MLL translocation events in AML cell lines.
We validated the HOXA association with þ 8 using the gene expression data set from Verhaak et al. 3 In this data set, there is some overlap of patient samples with the study described by Valk et al.
2 but this study included six additional þ 8 AML patients and was performed using a different Affymetrix platform (HGU133 plus2). Consistent with our previous observations, we observed high HOXA9, HOXA10 and HOXA1 expression in the þ 8, MLL and normal karyotype groups (Figure 4) . We used the data from Verhaak et al. 3 to determine whether HOXA9 expression in the þ 8 AML group was independent of NPM1, FLT3-ITD or FLT3-TKD mutations. Although the number of FLT3-TKD þ / þ 8 samples was too small for conclusive statistical analysis (3 out of the total 20 þ 8 AMLs analyzed), no statistically significant differences (t-test, P40.05) between the HOXA9 expression in þ 8 samples with and without the NPM1 KG1  GDM1  EM2  KU812  THP1  MV4II  HL60  HEL  PLB985  BV173  CMLT1  NALM1  K562  MEG01  ML2   10 KG1  GDM1  EM2  KU812  THP1  MV4II  HL60  HEL  PLB985  BV173  CMLT1  NALM1  K562  MEG01  ML2   10 mutation and with and without FLT3-ITD mutation were found (data not shown). This suggests that the association of þ 8 AML with increased HOXA9 expression is independent of these common mutations. Similarly, we found that high expression of HOXA10 and HOXA1 in the þ 8 samples was independent of the presence of the MLL translocation, FLT3-ITD, FLT3-TKD or NPM1 mutations (data not shown).
HOXA9 HOXA10
The mechanism underlying the upregulation of the HOXA genes in the þ 8 AML group is unknown. In AML with the t(9;11) translocations, altered HOX gene expression is associated with the aberrant function of the MLL fusion protein. 6 We have excluded samples with the t(9;11) (MLL translocation) in this analysis of þ 8 AML patients; however, we cannot exclude the presence of the MLL partial tandem duplications that can also upregulate HOXA9 expression. 7 In normal karyotype AML, the mechanism associated with increased expression of HOX genes appears to be distinct from AML with MLL fusions and may be associated with NPM1 mutations. 8 To explore potential mechanisms of increased HOX gene expression further we used the þ 8 gene set (90 genes) to The probability of achieving an optimal response to treatment in CML is most likely to be influenced by the variable capacity of a given patient's leukemia cells to accumulate intracellular imatinib (IM). The transport of IM into the cells is an active process mediated by the human organic cation transporter (hOCT1) protein, a membrane associated ATPdependent protein channel. 1 Recently we reported that higher levels of hOCT1 transcript levels in blood derived white cells (WBC) collected at diagnosis predicted for a 3-log reduction in BCR-ABL1 transcript levels (major molecular response, MMR) and also for greater degrees of transcript reduction in patients who had achieved complete cytogenetic responses (CCyR). 2 Investigators in Liverpool also showed that higher hOCT1 transcript levels in diagnostic WBC predicted for a better response to IM. 3 The mean hOCT1 mRNA level in pre-IM bone marrow mononuclear cells (MNC) was also reported to be lower in the patients who failed to achieve CCyR by 12 months of therapy. 4 However a recent study of total WBC collected from newly diagnosed patients before starting IM failed to confirm any correlation between hOCT1 transcript levels and response to IM. 5 These conflicting reports on the predictive value of hOCT1 transcript levels 2-5 might be due to the different target cells studied, to different primers and probes used to measure hOCT1 mRNA
